Medtronic, Nile Therapeutics to work on drug-device combo

02/28/2011 | American City Business Journals

Medtronic has agreed to partner with Nile Therapeutics to develop a peptide drug, called cenderitide, for heart failure and renal disease that can be delivered by its diabetes pump system. Under the agreement, Nile will focus on conducting a first-stage trial of the peptide, and Medtronic will provide financing and share its knowledge in developing drug-device combination products.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care